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Asthma and the outcome of sickle cell disease 
 
ABSTRACT 
 
Introduction: Sickle cell disease (SCD) is one of the commonest monogenetic diseases.  
Worldwide, there are 300,000 infants with sickle cell disease (SCD) born every year. 
Affected patients can die prematurely in their fifth decade as they suffer multi-organ damage, 
including pulmonary complications.  
Areas covered: This review describes the pathophysiology of SCD and its pulmonary 
complications and discusses the relationship between asthma and the outcomes of SCD. 
Patients with SCD and asthma, but importantly recurrent episodes of wheeze (which may not 
be due to asthma) have an increased risk of acute chest syndrome (ACS), painful crisis, 
stroke and all-cause mortality. In SCD, there is an increased pulmonary vascular volume, 
which is a response to their chronic anemia. Data from adult and paediatric cohorts show 
such haemodynamic changes result in airflow obstruction and hence wheezing. 
Expert commentary: The wheezing and lung function abnormalities which occur in SCD 
patients can be due to asthma, but in others reflects the vascular airway interaction occurring 
because of chronic anaemia. It is important to differentiate whether a SCD patient is 
wheezing due to asthma or SCD per se as it will affect the choice of appropriate treatment.    
 
Key words: acute chest syndrome, asthma, sickle cell disease, wheezing 
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1.    INTRODUCTION 
 
Sickle cell disease (SCD) is one of the commonest monogenetic diseases [1]. Worldwide, 
there are 300,000 infants with SCD born every year [2] and there are 200 million carriers of 
sickle cell trait. SCD was first described in 1910 by James Herrick when he observed 
“peculiar elongated and sickle-shaped red blood corpuscles” in blood films from an African-
American patient presenting with severe anaemia [3]. In 1949, Linus Pauling et al described 
SCD as the first “molecular disease” when they detected distinct electrophoretic anomalies in 
sickle haemoglobin [4]. Nowadays, the majority of patients with SCD in developed countries 
can expect to survive to adulthood [5], but the median survival is only in the fifth decade and 
many suffer multi-organ damage, including pulmonary complications [6].  Recent years have 
seen an increasing recognition of the importance of SCD-related cardiopulmonary disease, 
but there remains uncertainty regarding the role of asthma in the pulmonary complications 
[7]. Indeed, it is now clear that there are distinct respiratory phenotypes in SCD patients [8]. 
Hence, in this review we will describe the pathophysiology of SCD and the pulmonary 
complications and then review the literature to determine the relationship between asthma 
and this globally important haematological condition. 
 
1.1    The pathophysiology of sickle cell disease 
  
 
SCD is an autosomal recessively inherited haemoglobinopathy, most commonly arising from 
a point mutation in the gene coding for the beta-globin chain whereby valine is substituted for 
glutamic acid at position six.  This results in a haemoglobin molecule (HbS), with an altered 
net electric charge and a tendency to form polymers when the protein is in its T-conformation 
in the deoxy state. The resulting internal stress and deformation of the affected erythrocytes 
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alters their mechanical and rheological characteristics, with consequent cell damage, 
reduction in erythrocyte lifespan and chronic haemolysis [10].  Due to saturation of protective 
haemoglobin scavenger proteins, nitric oxide bioavailability is reduced and a state of nitric 
oxide resistance develops (Figure 1) [11, 12].  The overexpression of cell-cell and cell-
vascular adhesion molecules coupled with reduced erythrocyte membrane deformability 
promotes the formation of cellular aggregates and cell-endothelial adhesion. This results in 
injury to the vascular endothelium (Figure 2) [13], microvascular occlusion and downstream 
tissue hypoxia with consequent release of inflammatory cytokines and creation of a chronic 
pro-inflammatory state [14].  The lung is particularly prone to damage from these processes 
due to the low oxygen tensions found in the pulmonary venous system and the adverse 
impact of altered cell rheology on erythrocyte transit time, which prolongs the duration of 
exposure to the polymerisation-promoting environment.  Compound heterozygosity for HbS 
and a rarer haemoglobin variant, such as haemoglobin C, generally results in a milder 
phenotype, whilst co-inheritance of HbS with a mutation for beta-thalassemia, can produce a 
wide spectrum of clinical phenotypes [9]. 
 
1.2    The pulmonary complications of SCD 
 
1.2.1   Acute chest syndrome and sickle chronic lung disease 
Acute chest syndrome (ACS) is a major cause of morbidity being the second most common 
cause of hospital admission and can result in premature death [15]. ACS episodes may 
account for as many as 14-25% of sickle related deaths [16]. Patients with ACS have fever, 
chest pain, tachypnoea, cough, or wheezing, key to the diagnosis is radiological evidence of 
new pulmonary infiltrates [17].  The Cooperative Study of Sickle Cell disease reported a 29% 
incidence of ACS over a two-year period in a large cohort of subjects with HbSS disease 
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[17].  ACS episodes are associated with a deterioration of cardiac function and an increase in 
pulmonary vascular pressures. Those changes are associated with an increased risk of death, 
suggesting that at least a proportion of the mortality due to ACS may be due to the acute 
development, or exacerbation of pre-existing, pulmonary hypertension and cor pulmonale 
[18].  Dysfunction of the autonomic nervous system, as evidenced by a reduction in 
parasympathetic activity, appears to be more common in patients with a history of ACS, 
suggesting a neutrally-mediated component to ACS pathophysiology [19].  ACS episodes 
often occur in hospitalised adult patients with SCD where it is usually preceded by an acute 
vaso-occlusive pain crisis [15, 17].  An increased risk of ACS is associated with younger age, 
higher steady-state haemoglobin concentration, elevated steady-state leucocyte count, lower 
HbF concentration [20], a history of smoking or smoke exposure [21] and in children and 
young adults, a diagnosis of asthma [22, 23].  ACS episodes tend to be more severe in HbSS 
disease compared to other genotypes [20].  More than 50% of children with HbSS suffer at 
least one ACS episode in the first decade of life [16]. Lung function has been shown to 
deteriorate with increasing age in SCD children and the rate of decline to be greater in young 
children in whom ACS episodes are more common [24]. In one series, children under four 
years of age were at greatest risk of ACS episodes [25]. 
 
Adults with sickle cell disease can suffer from parenchymal lung disease and pulmonary 
vascular disease.  This spectrum of abnormalities is commonly referred to as ‘sickle chronic 
lung disease’ (SCLD).  In some cases, these processes may progress to restrictive lung 
disease and/or pulmonary hypertension.  There is no curative treatment for SCLD, but ACS 
episodes are the most significant risk factor. Hence, prevention and optimisation of treatment 
of ACS episodes would improve the long-term outcome of SCD. 
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1.2.2 Pathogenesis of acute chest syndrome 
The incidence of ACS episodes is commoner and the episodes more severe in those with 
HbSS than HbSC [26]. Whilst some early reports suggested that the ACS incidence was 
lower in patients with the Arab-Indian haplotype which is associated with a higher HbF level, 
recent data indicate incidence is similar to that observed in African haplotypes [27]. The risk 
for ACS is also increased by certain endothelin NO synthase gene polymorphisms [28]. 
  
In both adults and children, pulmonary infection is implicated in many cases of ACS.  In a 
large cohort of patients in the USA, an infectious pathogen was isolated in 54% of admissions 
for ACS from a total of 671 episodes [15]. These were predominantly atypical bacteria and 
viruses; community acquired encapsulated bacteria were only found in a minority of cases (< 
10% of ACS episodes).   A total of twenty-seven different pathogens were identified of which 
C. pneumoniae was the most frequent, followed by M. pneumoniae and respiratory syncytial 
virus. Parvovirus was associated with severe reticulocytopenia [15].  Compared to patients 
who were infected with mycoplasma strains, patients with chlamydia infections were more 
likely to suffer a vaso-occlusive event during their hospital stay and had higher mean 
haemoglobin levels [15].   Seasonal influenza infection has also been linked to ACS [29, 30].  
Infection may precipitate ACS due to an enhanced susceptibility to inflammatory 
provocation.  In studies of transgenic mice expressing human HbS, SCD mice exhibited a 
heightened susceptibility to inflammatory provocation by lipopolysaccharide and bacterial 
endotoxin, resulting in lung injury at levels of endotoxin that had no adverse effect on wild-
type mice [31, 32].    
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Fat emboli may also play a significant role in the pathogenesis of ACS.  Severe vaso-
occlusive pain crises, typically involving the proximal skeleton, result in bone marrow 
infarction and necrosis resulting in the release of fatty contents into the bloodstream.   In the 
pulmonary vasculature severe lung inflammation, acute pulmonary hypertension and 
hypoxaemia are triggered by means of direct mechanical occlusion and inflammation [33-36].  
Fat-laden alveolar macrophages obtained during bronchoscopy are diagnostic of pulmonary 
fat embolism.  In the national ACS study cohort, fat embolism was diagnosed in 16% of ACS 
cases in adults and children [15].  Another study found that patients with ACS in whom lipid-
laden macrophages were identified in induced sputum followed a more severe clinical course, 
with more severe extra-thoracic pain and a greater incidence of neurological symptoms 
compared to patients without evidence of fat embolus [35].  
 
Episodes of ACS are frequently temporally related to infarcts of the ribcage [37].  Subsequent 
restriction of chest wall motion and alterations in breathing pattern due to the pain and 
discomfort result in atelectasis and hypoventilation which contribute to the development ACS 
[38-40].  A study of breathing patterns adopted by SCD patients with both thoracic and non-
thoracic pain found that rapid shallow breathing is a feature of patients with thoracic bone 
pain [41].   In SCD children admitted to hospital with acute back and/or chest pain, incentive 
spirometry has been used to improve ventilation and significantly reduced the incidence of 
acute pulmonary complications during the period of admission [42].  The use of opiates for 
analgesia during painful crisis has also been linked to hypoventilation and development of 
ACS [43]. 
 
Asthma has been linked to an increased risk of ACS.  In a retrospective review of 139 
children with SCD, those with asthma had four times as many ACS episodes as the non-
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asthmatics, they also had an increased length of hospitalisation [23].  In another retrospective 
study, amongst 96 children with SCD, those with asthma had a significantly greater 
frequency of ACS episodes [44]. A retrospective review of electronic medical records of a 
USA children’s hospital highlighted that ACS episodes were more common in those with 
asthma [45]. Asthma is also associated with recurrent ACS episodes. In a study of 80 SCD 
children, asthma (80% versus 40%) and particularly atopic asthma (53% versus 12%), were 
more common in children who had suffered recurrent episodes of ACS than in those who had 
suffered a single or no episode [46].  In a subsequent study, Boyd et al found that children 
with SCD and asthma suffered twice as many ACS episodes as those without asthma (0.39 
vs. 0.2 episodes per patient-year) and that the children with asthma developed their first ACS 
episode at a significantly younger age (2.4 versus. 4.6 years) [22].  Those results were 
consistent with a study highlighting that a greater number of the children who had an ACS 
episode compared to those who had not were taking anti-asthma medication. Importantly, the 
children with a history of ACS had been diagnosed as asthmatic at a median of 3.5 (range 
0.5-7) years prior to their first ACS episode, suggesting that asthma may predispose children 
with SCD to subsequent ACS episodes [47].  Those results were similar to those obtained in a 
later retrospective analysis of 297 children with ACS which found that SCD children with a 
diagnosis of asthma had an increased rate of ACS (0.31 events per patient-year vs. 0.16 
events per patient-year) compared to those who did not [48].  
 
1.3   Asthma and SCD 
 
A diagnosis of asthma may increase the risk of other complications. Patients with SCD and 
asthma or a history of recurrent episodes of wheeze have been reported to have a significantly 
increased risk of painful crisis [49, 50], stroke [44] and all-cause mortality [51, 52]. Indeed, 
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data from experimental models of asthma in SCD mice support an asthma-SCD synergy.  
Using sensitisation with ovalbumin to generate an experimental asthma in chimeric mice 
expressing human HbA or HbS and wild-type controls, [53], Nandedkar et al demonstrated 
significantly greater mortality, following the primary sensitisation dose, in the SCD mice 
compared to the controls (10% versus 0%, p<0.01) [53].  In both SCD and wild-type mice, 
sensitisation was associated with markers of asthma including blood eosinophilia, 
peribronchial and perivascular eosinophil infiltration, elevated serum IgE, and basement 
membrane thickening, some of which showed a dose-response pattern in both HbA and wild-
type mice.  In the SCD mice, however, the peak inflammatory response occurred at a low 
dose of ovalbumin and, following high-dose aero-sensitisation 30% of the SCD mice died 
compared to 4% and 0% mortality in the HbA and wild-type groups, respectively [53].  
Those data suggest a role for both SCD and asthma-related lung inflammation and that the 
two pathologies interact to amplify the inflammatory response. 
 
1.3.1   Is asthma increased in SCD? 
Asthma may be more common in children with SCD than the general population [46, 54], but 
this is not a universal finding.  Making the diagnosis of asthma in children with SCD can be 
difficult as common asthma symptoms, such as wheeze and shortness of breath, can also be 
seen in SCD.  In Nigerian children, wheezing with or without a cold was much more common 
in those with SCD, almost ten times greater; the only variable associated with wheezing was 
SCD status [55]. Furthermore, in a longitudinal study, cough and wheeze events were 
temporarily associated with increased pain in individuals with SCD without asthma. The 
authors, however, acknowledge their sample size was small and not all asthma diagnoses may 
have been correctly classified [56]. Asthma is characterised by variable airflow obstruction 
and bronchial hyper-reactivity resulting from chronic inflammation [57].  The diagnosis is 
9 
 
made more reliably by evidence of reversible airflow obstruction, laboratory markers of 
atopy or inflammation and/or a family history of atopic or allergic disease, but in practice the 
diagnosis is often made on the basis of the clinical presentation alone [58].  Indeed, in the 
majority of studies of asthma in SCD, the diagnosis was made by medical records review  
[22, 23, 44] or current use of anti-asthma [22, 59] medication.  When assessing BHR, it is 
important to note that some children may only respond to an exercise challenge and others 
only to a cold air challenge [60] and that bronchial challenge testing may precipitate a painful 
crisis. Whilst bronchial hyper-responsiveness (BHR) may be more prevalent in patients with 
SCD compared to the general population, it can be independent of an asthma diagnosis [ 46, 
61, 62].  BHR is associated with both elevated serum IgE and lactate dehydrogenase (LDH) 
levels [63], suggesting a potential role for intravascular haemolysis in mediating reactive 
airways disease in SCD. Furthermore, Chaudry et al reported that airflow obstruction was 
present even in young children with SCD, but this was not associated with increased 
methacholine sensitivity or elevated exhaled nitric oxide [64], both key asthma biomarkers.  
In a subsequent study, steady state exhaled nitric oxide was not associated in SCD children 
with an asthma diagnosis, wheezing symptoms, lung function measures or prior sickle cell 
morbidity but was associated with markers of atopy and increased risk of future ACS 
episodes [65].  Those data suggest that mechanisms other than asthma may also mediate 
wheeze, in patients with SCD. The differentiation as to whether a SCD patient is wheezing 
die to asthma or SCD per se is important as it will affect the treatment used.  Systemic 
corticosteroids are often used in the management of asthma exacerbations, but can cause an 
increase in painful crises and perhaps cerebrovascular accidents in SCD [66, 67]. 
Furthermore, in a historical review, SCD children with ACS episodes who received inhaled 
corticosteroids had no significant differences in outcomes, regardless of whether they had a 
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diagnosis of asthma [68]. If the wheezing is due to SCD per se then SCD therapies are 
indicated. 
 
 
1.3.2  Potential mechanisms for reactive airways disease in SCD  
A number of potential pathways for mediation of reactive airways disease in SCD have been 
identified, some of which are distinct from those seen in asthma and arise as a consequence 
of SCD per se.  In murine models of SCD, the pro-inflammatory state present in SCD has 
been shown to prime the bronchial mucosal immune system for allergen-induced 
inflammation [69] with increased total lymphocytes, CD8+ T cells and interleukins in 
bronchoalveolar lavage fluid, as well as increased CD4+, CD8+ and regulatory T cells in 
lung tissue and hilar lymph nodes.  One proposed mechanism for increased airway 
inflammation in SCD children is that haemolysis contributes to airway changes similar to 
those found in asthma.  Haemolysis causes hydrolysis of membrane phospholipids into 
arachidonic acid, which leads to formation of leukotriene B4 which is also associated with 
eosinophilic asthma [70].  Elevated leukotriene levels have been found in SCD in both 
murine and human studies [70].  Placenta growth factor, which is elevated in SCD has been 
shown in a mouse study to exacerbate airway hyperresponsiveness and may link the 
leukotriene and Th2-mediated pathways in asthma [71].  Other studies have also proposed 
that the effect of haemolysis on nitric oxide may cause the airway changes seen in SCD.  
Nitric oxide bioavailability is reduced by haemolysis by two mechanisms.  Firstly, it is 
consumed by the free haemoglobin which results from the haemolysis.  Secondly, lysed 
erythrocytes release arginase, reducing the availability of arginine for synthesis of nitric 
oxide.  This causes vasoconstriction, endothelial activation and proliferation [ 70, 72].  
Exhaled nitric oxide, a marker of asthma and steroid response, is reduced in SCD patients 
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[72].  Comparison of SCD children with age- and ethnicity-matched controls demonstrated 
the former did not have elevated airway nitric oxide flux nor did the levels correlate with 
airways obstruction [73].  Elevated alveolar pulmonary NO production, however, 
significantly correlated with pulmonary blood flow in children with SCD, which may reflect 
increased shear stress due to the hyper-dynamic circulation [73]. Further differences in the 
pathogenesis of the inflammation seen in SCD and in asthma have been reported.  In SCD 
patients, airway obstruction and hyper-responsiveness correlated with markers of haemolysis 
and IgE levels, but unlike in asthmatics, they did not with eosinophil count, skin prick test or 
exhaled nitric oxide [70].  Furthermore, murine models have shown increased IL-6 and MCP-
1 in SCD, which are associated with monocyte activation but not with allergic asthma [70].   
 
1.3.3   A non-inflammatory mechanism for airflow obstruction: a vascular-airway interaction   
Children and adults with SCD have an increased pulmonary vascular volume, which is a 
response to their chronic anemia resulting in a raised cardiac output and increased vascular 
recruitment and distension [74-76].  Data from adult and paediatric cohorts suggest such 
haemodynamic changes drive a pulmonary vascular-airway interaction which mediates a non-
inflammatory form of airflow obstruction in SCD [77, 78].  In a cohort of adults with HbSS 
disease, two measures of small-vessel size were derived from CT scans and were 
independently linked to reductions in FEV1, VC and FEF25/75 and to increased respiratory 
system resistance and RV:TLC [77]. Those results were consistent with those from a cohort 
of children, in whom pulmonary capillary blood volume was negatively correlated with 
FEV1, VC and FEF25-75 and positively correlated with respiratory system resistance [78].  The 
negative relationship between measures of pulmonary vascular volume and VC, FEV1 and 
FEF25/75 and a positive relationship with RV, RV:TLC and respiratory system resistance 
suggest that the elevated pulmonary vascular volume was related to an obstructive defect.  
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Furthermore, measures of pulmonary vascular volume correlated with reduced haemoglobin 
concentration in both studies, suggesting that haemolysis and chronic anaemia was a key 
process in causing the pulmonary function abnormalities [77, 78]. In addition, a prospective 
three-dimensional echocardiography/Doppler study of 122 adults with SCD and 30 ethnicity 
matched healthy controls demonstrated that tricuspid valve regurgitation was rarely related to 
haemodynamically significant pulmonary hypertension, but rather elevated cardiac output, 
biventricular dilation and volume overload, likely related to the chronic anaemia [79]. In a 
subsequent study, increased pulmonary capillary blood volume and airways resistance were 
seen to occur immediately following blood transfusion in children with SCD.  Those changes 
were accompanied by significant reductions in FEV1, VC and FEF25-75 and the change in lung 
function correlated with the increase in pulmonary capillary blood volume [80]. Those results 
further support a vascular-airway interaction. 
 
1.3.4 Therapies to improve lung function in SCD patients  
Whilst randomised controlled trials of hydroxyurea incorporating pulmonary functions test 
outcomes are lacking, analyses of observational data suggest that hydroxyurea significantly 
attenuates the age-related decline in forced expiratory volume in one second and forced vital 
capacity in children with SCD [81].  Whether this reflects a reduction in ACS frequency or a 
direct effect of improved haematological characteristics on cardiopulmonary function, or a 
combination of the two is uncertain, but the resolution of these questions should form a key 
part of future efforts to develop SCD-specific treatments to reduce respiratory complications. 
 
1.3.5  SCD-related respiratory disease in low- and middle-income countries 
SCD is a global disease, and the greatest burden of SCD-related morbidity is borne by low- 
and middle-income countries (LMICs).  Detailed phenotypic data from many of those 
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countries, especially those in sub-Saharan Africa and the Indian sub-continent, are sparse 
compared to Western Europe and the USA.  Recent data, however, suggest that the 
prevalence of wheeze, airflow obstruction and ACS in some LMIC countries are broadly 
similar to that observed in high-income settings [46, 52, 55].  In contrast, a small study of 25 
Malawian children reported a predominantly restrictive pattern, with no evidence of 
obstructive lung disease or increased prevalence of wheeze. The authors suggested that 
physiological evidence of airflow obstruction may be masked, in certain contexts, by the 
early onset of restrictive lung disease [83].   Interestingly, in a large study (n=8504) of 
Jamaican cohorts [84] significant independent associations were found between a history of 
“respiratory problems” (an aggregate term which included asthma and ACS) and climatic 
conditions, proximity to industrial activity and urban residence.  Respiratory problems in 
SCD patients in LMIC settings thus may be modulated by complex interactions between 
disease status, industrial and economic development, and increasing urbanisation,     
 
2.   Conclusion 
 
We have highlighted that asthma is associated with increased SCD complications, but a 
physician’s diagnosis of asthma is inadequate to determine causation or appropriate 
treatment. Wheezing can occur due to SCD per se and wheezing in the absence of a diagnosis 
of asthma can increase SCD pulmonary complications. Importantly, lung function 
abnormalities and wheezing may occur from a vascular-airway interaction due to chronic 
anaemia which results in an increased pulmonary vascular volume. It is thus essential if a 
SCD child’s treatment is to be optimised to determine by appropriate investigation if indeed 
they do have asthma. We suggest that pulmonary function testing, including measurement of 
lung volumes and bronchodilator responsiveness and skin-prick testing to assess atopy, 
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should form part of the routine assessment of patients with SCD, especially those with 
respiratory symptoms or a history of ACS.  
 
 
 
3.  Expert commentary 
 
SCD is an important global health problem as the associated acute and chronic pulmonary 
complications cause a high burden of morbidity and early mortality.  Asthma has long been 
associated with SCD-related complications, including acute chest syndrome, but in recent 
years there has been appreciation of the complexity of the relationship between asthma, SCD 
and pulmonary dysfunction. This has led to an awareness that current approaches to the 
diagnosis and management of asthma and wheezing in SCD patients are inadequate. Indeed, 
there are no appropriately designed studies to assess whether SCD therapies such as 
hydroxyurea or asthmatic preventions or treatments improve the long term outcomes of 
children with SCD. Furthermore, if the clinical management of children and adults with SCD 
is to be optimized, an improved understanding of the phenotypic complexity and the 
mechanistic basis of SCD-related cardiopulmonary disease will be required.  Such an 
understanding will form the basis of new diagnostic approaches and the development of 
SCD-specific treatments.  Given the degree of phenotypic diversity, SCD is a prime 
candidate for the development and implementation of a “stratified medicine” approach to 
treatment. This, however, will require a coordinated effort to integrate the efforts of basic, 
translational, statistical and computational researchers and clinicians within a strong 
collaborative framework, with data sharing and pooling of resources.  A key component of 
such a programme will be the extension of research efforts from Europe and North America 
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to the low and middle income countries who bear the greatest burden of SCD-related 
morbidity.  The development of such large-scale and integrated research efforts will present 
formidable challenges, but we can look to colleagues working in other parts of respiratory 
medicine for inspiration. The success achieved in understanding and treating the pulmonary 
and non-pulmonary complications of cystic fibrosis is of particular note and may provide a 
template for future efforts in SCD.    The success in CF has recently been discussed [82] and 
includes capture of routine clinical and physiological data at scale by means of patient 
registries to identify risk factors for morbidity.  The results have then been used to inform the 
development of rigorous mechanistic studies to elucidate disease-specific physiological, 
cellular and genetic pathways potentially amenable to pharmacological modification. The 
data has then been synthesised to develop evidence-based clinical guidelines and standardised 
protocols for diagnosis and treatment.  We hope that similar efforts in SCD will yield equally 
impressive results. Assessment of wheezing, breathlessness and exercise intolerance should 
form a routine part of the assessment of parents  with SCD and, where resources are 
available, pulmonary function testing should be conducted routinely  Affected patients should 
be managed by a multidisciplinary team with input from a respiratory specialist (Figure).   
 
4.   Five-year view 
  
In the coming years, we expect to see the development of large-scale patient registries to 
capture, on a routine basis, a wealth of clinical data on large cohorts of adults and children 
with SCD from Africa, the Caribbean, the Americas, Europe, the Middle East and the Indian 
sub-continent.  Deep phenotyping will be key, including clinical outcomes and genetic, 
physiological and environmental data.  Such data will facilitate the use of modern statistical, 
machine learning and systems biology approaches to identify new targets for specific SCD 
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pathologies and will form the basis of large-scale clinical trials of personalised medicine 
approaches to the treatment SCD-related lung disease.     
 
 
 
5.  Key issues 
• Asthma has been associated with SCD and with an increased incidence and/or 
severity of complications. 
• Recent work has demonstrated alternative inflammatory and non-inflammatory 
pathways, intrinsic to SCD, which may be responsible for some of the asthma-like 
symptoms in SCD.  These include haemolysis-mediated lung inflammation and 
extrinsic airway compression due to increased pulmonary vascular volume. 
• The existence of alternative mechanisms for airflow obstruction in SCD complicates 
making a diagnosis of asthma, but provides new targets for therapeutic intervention 
and prevention of SCD-related cardiopulmonary morbidity. 
• New research strategies are required to understand the mechanistic basis of SCD-
related airflow obstruction, to develop diagnostic tests for asthma in patients with 
SCD, and to optimise the clinical management of individuals with this debilitating 
disease. 
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FIGURE LEGENDS 
Figure 1: Vasculopathy in SCD. Polymerisation of HbS leads to reduced erythrocyte lifespan 
and increased intravascular haemolysis.  Circulating nitric oxide (NO) levels are reduced due 
to scavenging by free HbS, free radical generation by xanthine oxidase, superoxide (O2
-) and 
reduced bioavailability of substrates such as arginine (Arg) for nitric oxide synthase (NOS) 
due to arginase-1 mediated catabolism.  These processes result in haemolytic anaemia and a 
chronic vasculopathy characterised by smooth muscle proliferation and endothelial 
dysregulation.  
 
Figure 2: Vaso-occlusion in SCD.  Deoxygenation of HbS-bearing erythrocytes causes HbS 
polymerisation and erythrocyte sickling.  Leukocytes and polymerised erythrocytes form 
aggregates which adhere to endothelial cells via interaction of the α4β1 molecule with 
vascular-cell adhesion molecule-1 (VCAM-1), a process which is promoted by increased 
VCAM-1 expression arising from the inflammatory milieu present in persons with SCD.  
This process results in microvascular occlusion and vaso-occlusive pain crises, including 
ACS.   
 
Figure 3:  Algorithm to investigate wheezing child with SCD  
 
 
 



